Literature DB >> 11829864

[The levels of renin activity, angiotensin converting enzyme and angiotensin II in cirrhotic patients with ascites undergoing portacaval shunt].

Z Zhang1, H Feng, X Leng, F Ma, B Wang, R Du.   

Abstract

OBJECTIVE: To investigate the changes of plasma renin activity (PRA), angiotensin converting enzyme (ACE), angiotensin II and portal venous pressure (PVP) in cirrhotic patients with ascites undergoing portacaval shunt.
METHODS: Serum PRA, ACE, A II levels in portal vein, artery, peripheral vein and PVP were measured in 16 cirrhotic patients with ascites before and after portacaval shunts and in control group of 16 cases of gastrointestinal carcinoma. By light colorimetric analysis and radio-immunization assay.
RESULTS: PRA, ACE, A II levels and PVP of pre- and after portacaval shunt were significantly higher in cirrhotic patients than the control group (P < 0.05), and they were significantly decreased after the shunt in the cirrhotic patients (P < 0.05). The PVP was in positive correlation to the levels of serum ACE in cirrhotic patients (r = 0.48, P < 0.01).
CONCLUSIONS: The levels of serum PRA, ACE, A II and PVP decreased significantly in cirrhotic patients with portal hypertension after portacaval shunts. It may be major causes of ascites disappearance in cirrhotic patients after portacaval shunt.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11829864

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

1.  Clinical analysis of surgical treatment of portal hypertension.

Authors:  Xin-Bao Xu; Jing-Xiu Cai; Xi-Sheng Leng; Jia-Hong Dong; Ji-Ye Zhu; Zhen-Ping He; Fu-Shun Wang; Ji-Run Peng; Ben-Li Han; Ru-Yu Du
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 2.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.